# US 7,744,886 B2 · Methods for interfering with rank signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,886 B2
- Document ID: US7744886B2
- Status: Granted
- Kind: B2
- Application number: 12/214,914
- Filed: 2008-06-24
- Published: 2009-01-15
- Granted: 2010-06-29
- Earliest claimed: 1996-12-23
- Assignees: Immunex Corporation
- Inventors: Dirk M Anderson
- Web page: https://patentgrep.com/patent/US7744886B2

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/435: from animals; from humans
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/7151: {for tumor necrosis factor [TNF], for lymphotoxin [LT]}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are methods for interfering with RANK signaling by administering blocking antibodies that bind a RANKL polypeptide and inhibit the binding of the RANKL polypeptide to a RANK polypeptide.

## Claims

### Claim 1

A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling.

### Claim 2 (depends on 1)

A method of claim 1, wherein the blocking antibody is a monoclonal antibody.

### Claim 3

A method of interfering with RANK signaling comprising administering an effective amount of a blocking antibody, wherein the blocking antibody binds to a fragment of a human RANKL polypeptide as shown in SEQ ID NO:13 and inhibits the binding of the human RANKL polypeptide to a human RANK polypeptide as shown in SEQ ID NO:6, thereby inhibiting RANK signaling, wherein the fragment is selected from the group consisting of
a) an extracellular domain comprising amino acids 69-317 of SEQ ID NO:13, and
b) a receptor binding domain comprising amino acids 162-317 of SEQ ID NO:13.

### Claim 4 (depends on 3)

A method of claim 3, wherein the blocking antibody is a monoclonal antibody.